Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease Risk
Can you apply?
This grant is for researchers and institutions seeking to fund interdisciplinary research on the biological mechanisms underlying resilience to Alzheimer's and related dementias (ARD). Eligible applicants typically include academic research institutions, medical centers, nonprofit research organizations, and other eligible entities (including small businesses with research capabilities) at domestic and international locations. Research must be hypothesis-driven and investigate why some individuals at genetic or biomarker risk for ARD remain cognitively intact or show resistance to disease development. The program emphasizes collaborative, multidisciplinary approaches drawing from neuroscience, genetics, immunology, and related fields. Both individual research projects and team-based investigations are supported, with funding mechanisms available for early-career researchers through more established investigators.
Key dates
- Sep 3, 2025 Applications open
- Jun 5, 2026 Application deadline in 4 days
- Apr 5, 2027 Award announced
- Apr 5, 2027 Project start
This grant is for researchers and institutions seeking to fund interdisciplinary research on the biological mechanisms underlying resilience to Alzheimer's and related dementias (ARD). Eligible applicants typically include academic research institutions, medical centers, nonprofit research organizations, and other eligible entities (including small businesses with research capabilities) at domestic and international locations. Research must be hypothesis-driven and investigate why some individuals at genetic or biomarker risk for ARD remain cognitively intact or show resistance to disease development. The program emphasizes collaborative, multidisciplinary approaches drawing from neuroscience, genetics, immunology, and related fields. Both individual research projects and team-based investigations are supported, with funding mechanisms available for early-career researchers through more established investigators.
Program description
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) that builds upon its investment in data-driven approaches for the purpose of defining molecular mechanisms of resilience in the presence of various types of Alzheimer’s disease (AD) and AD-related dementias (ADRD) risk. The goal of this NOFO is to build a robust program that integrates epidemiologic, genomic, and mechanistic research through the use of data driven, systems-based approaches (including the use of artificial intelligence and/or machine learning methods) to discover the molecular/cellular determinants of resilience to AD/ADRD risk across representative populations. The initiative will support the generation of high-dimensional molecular data from brain and peripheral tissues, including longitudinal data, to enable dynamic modeling of resilience mechanisms and to discover molecular predictors of resilience.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
Details
This grant is for researchers and institutions seeking to fund interdisciplinary research on the biological mechanisms underlying resilience to Alzheimer's and related dementias (ARD). Eligible applicants typically include academic research institutions, medical centers, nonprofit research organizations, and other eligible entities (including small businesses with research capabilities) at domestic and international locations. Research must be hypothesis-driven and investigate why some individuals at genetic or biomarker risk for ARD remain cognitively intact or show resistance to disease development. The program emphasizes collaborative, multidisciplinary approaches drawing from neuroscience, genetics, immunology, and related fields. Both individual research projects and team-based investigations are supported, with funding mechanisms available for early-career researchers through more established investigators.
How to apply
Application links
Key dates & requirements
Required documents
- Completed SF-424 (R&R) application form with signatures
- Project narrative/Research strategy (typically 15 pages including specific aims, significance, innovation, approach, timeline)
- Biosketch (NIH format) for senior personnel showing relevant expertise
- Budget and budget justification
- Institutional commitment letters and administrative information
- Literature citations and appendices (if applicable)
- Protection of human subjects documentation (if human subjects research)
- Animal care and use protocol (if animal studies)
- Data management and sharing plan
- Vertebrate animals section (if applicable)
Program contact
- 👤 Suzana Petanceska, Ph.D.
- 📧 petanceskas@nia.nih.gov
- 📞 301-496-9350
Funding track record
Recent awards under CFDA 93.866 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$463,372,200
-
$172,327,224
-
$115,145,694
-
$99,649,073
-
$93,275,174
-
$78,657,309
-
$75,825,492
-
$75,398,895
-
$70,985,470
-
$64,812,576
Top States by Funding
- MI 2 awards $511.9M
- CA 8 awards $511.1M
- MO 8 awards $437.0M
- IN 4 awards $303.9M
- PA 6 awards $298.0M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.866). How funding has trended year over year.
| 2024 | $3,746,886,731 | |
| 2025 | $3,777,464,644 | |
| 2026 est. | $261,814,471 |
FAQ
Who is eligible to apply for this grant?
Eligible applicants include nonprofit research institutions, academic medical centers, universities, government agencies, small businesses with research capacity, and other domestic and international organizations. Individual researchers must be affiliated with an eligible institution.
What types of research does this grant support?
The grant funds interdisciplinary research examining why some individuals develop resilience to Alzheimer's disease despite genetic or biomarker risk factors. Studies may focus on protective biological mechanisms, genetic modifiers, brain reserve, immune factors, lifestyle interactions, and related mechanisms.
What is the typical funding level and project duration?
Funding levels and project periods vary by mechanism (R01, R03, R21, etc.), typically ranging from 2-5 years. Check the specific notice or FOA for exact budget guidelines and allowable direct costs.
How competitive is this funding opportunity?
NIH research grants are highly competitive, typically with success rates of 10-25% depending on the institute/center and mechanism. Strong preliminary data, clear hypotheses, and experienced research teams are essential.
Are there specific application deadlines?
Standard application deadlines may apply (often around specific receipt dates throughout the year). Check Grants.gov and the NIH program announcement for exact deadline dates and whether rolling submission is allowed.
💡 Tips for applicants
- Build a strong rationale grounded in existing literature showing evidence of resilience phenotypes and identifying knowledge gaps; emphasize how your work will advance understanding of disease resistance mechanisms.
- Assemble an interdisciplinary team with complementary expertise (e.g., neuroscientist, geneticist, statistician, clinician) to address the complex biology; clearly define roles and show track records of collaboration.
- Use preliminary data strategically to demonstrate feasibility; pilot studies on resilience cohorts, novel biomarkers, or animal models significantly strengthen applications.
- Design rigorous, well-powered study designs with appropriate controls; clearly articulate specific aims that are measurable and distinct, and explain how each aim addresses resilience biology rather than disease pathology.
- Address diversity and inclusion proactively by recruiting from underrepresented populations in dementia research and explaining how your findings will benefit diverse communities at risk for ARD.
⚠️ Common mistakes
Many applications fail because they focus narrowly on disease mechanisms rather than resilience—reviewers want to understand *why risk doesn't lead to disease*, not just how disease develops. Weak preliminary data or lack of evidence for a novel approach also commonly leads to rejection. Additionally, applications that lack clear interdisciplinary collaboration or sufficient statistical/methodological rigor often score poorly; NIH emphasizes rigorous science and team expertise to tackle complex biology.
Similar grants
- OPEN 27-0343-10 FFY27 Local Agency General Non-Enforcement — Illinois Department of Transportation
- ROLLING Annual Agency Threshold Application Applicants for Funding Start Here — Texas City of Austin - Austin Public Health
- CLOSED Virginia’s Black Indigenous and People of Color (BIPOC) Grant – FY26 — Virginia The Virginia Department of Historic Resources
- ROLLING RTAP Grant Program (Rolling) — Virginia Department of Rail and Public Transportation
- ROLLING Rail Industrial Access Grant (RIA) — Virginia Department of Rail and Public Transportation